244 related articles for article (PubMed ID: 20028765)
1. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
Mahalingam D; Medina EC; Esquivel JA; Espitia CM; Smith S; Oberheu K; Swords R; Kelly KR; Mita MM; Mita AC; Carew JS; Giles FJ; Nawrocki ST
Clin Cancer Res; 2010 Jan; 16(1):141-53. PubMed ID: 20028765
[TBL] [Abstract][Full Text] [Related]
2. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
[TBL] [Abstract][Full Text] [Related]
3. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
4. Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.
Carew JS; Espitia CM; Zhao W; Mita MM; Mita AC; Nawrocki ST
Mol Cancer Ther; 2015 Jun; 14(6):1404-13. PubMed ID: 25808836
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
6. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
8. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
9. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
12. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
Sato A; Asano T; Ito K; Asano T
J Urol; 2012 Dec; 188(6):2410-8. PubMed ID: 23088964
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of lung resistance related protein by RNA interference targeting survivin induces the reversal of chemoresistances in hepatocellular carcinoma.
Song X; Wang JB; Yin DL; Yang HY; Liu LX; Jiang HC
Chin Med J (Engl); 2009 Nov; 122(21):2636-42. PubMed ID: 19951584
[TBL] [Abstract][Full Text] [Related]
18. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus.
Sadler TM; Gavriil M; Annable T; Frost P; Greenberger LM; Zhang Y
Endocr Relat Cancer; 2006 Sep; 13(3):863-73. PubMed ID: 16954435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
